You are here:

infliximab (Remicade)


Following a full submission

infliximab (Remicade®) is accepted for use within NHS Scotland for the treatment of severe, active Crohn's disease, in paediatric patients aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies.

In an open label study 88% of patients had a clinical response following the induction regimen and this was maintained at one year in significantly more patients receiving infliximab every 8 weeks compared with every 12 weeks.

Drug Details

Drug Name: infliximab (Remicade)
SMC Drug ID: 448/08
Manufacturer: Schering-Plough Ltd
Indication: Treatment of severe, active Crohn’s disease in paediatric patients
BNF Category:
Sub Category: 1.5 Chronic bowel disorders
Submission Type: Full submission
Status: Superseded
Date Advice Published: 10 March 2008